AZD5156: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   All outcomes  
Meta-analysis1 study · 57 patientsc19early.org

AZD5156 for COVID-19

Serious outcome risk
AZD5156
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−139%
Mortality (1)−139%
RCTs (1)−139%
Prophylaxis (1)−139%
00.511.5+
← AZD5156
reduces riskIncreased
risk →
c19early.org
October 2026

AZD5156 COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Haidar (DB RCT)−139%2.39 · 0.10–55.82death1/410/16SUPERNOVA
Prophylaxis−139%2.39 · 0.10–55.821/410/16139% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6
All studies−139%2.39 · 0.10–55.821/410/16139% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.600.511.52+
Rotate screen for more detailsIncrease width for more details
← AZD5156
reduces riskAZD5156
increases risk →
c19early.org
October 2026

AZD5156 COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Haidar (DB RCT)−139%2.39 · 0.10–55.821/410/16SUPERNOVA
Prophylaxis−139%2.39 · 0.10–55.821/410/16139% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6
All studies−139%2.39 · 0.10–55.821/410/16139% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.600.511.52+
Rotate screen for more detailsIncrease width for more details
← AZD5156
reduces riskAZD5156
increases risk →
c19early.org
October 2026

AZD5156 COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Haidar (DB RCT)−139%2.39 · 0.10–55.82death1/410/16SUPERNOVA
Prophylaxis−139%2.39 · 0.10–55.821/410/16139% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6
All studies−139%2.39 · 0.10–55.821/410/16139% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.600.511.52+
Rotate screen for more detailsIncrease width for more details
← AZD5156
reduces riskAZD5156
increases risk →
c19early.org
October 2026

AZD5156 COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Haidar (DB RCT)−139%2.39 · 0.10–55.82death1/410/16SUPERNOVA
Prophylaxis−139%2.39 · 0.10–55.821/410/16139% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6
All studies−139%2.39 · 0.10–55.821/410/16139% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.600.511.52+
Rotate screen for more detailsIncrease width for more details
← AZD5156
reduces riskAZD5156
increases risk →
c19early.org
October 2026

AZD5156 COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Haidar (DB RCT)−139%2.39 · 0.10–55.821/410/16SUPERNOVA
Prophylaxis−139%2.39 · 0.10–55.821/410/16139% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6
All studies−139%2.39 · 0.10–55.821/410/16139% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.600.511.52+
Rotate screen for more detailsIncrease width for more details
← AZD5156
reduces riskAZD5156
increases risk →